Candid Therapeutics Expands T-Cell Engager Portfolio with Three New R&D Collaborations

Candid Therapeutics' Expansion:
Candid Therapeutics has entered into three new research and development (R&D) collaborations to further build out its portfolio of T-cell engagers (TCEs) aimed at treating autoimmune diseases4.

T-Cell Engagers (TCEs):
TCEs are a class of therapeutic agents designed to engage T-cells in the immune system to target specific diseases, including autoimmune conditions.

Strategic Partnerships:
These collaborations are part of Candid Therapeutics' strategy to expand its capabilities and offerings in the biotechnology sector, focusing on innovative treatments for autoimmune diseases.

Disease Focus:
The partnerships are aimed at developing treatments for autoimmune diseases, which are conditions where the body's immune system mistakenly attacks its own tissues.

R&D Collaborations:
The new collaborations underscore Candid Therapeutics' commitment to advancing research and development in the field of TCEs, leveraging partnerships to accelerate the discovery and development of new therapies.

Sources:

4. https://c.firstwordpharma.com/firstwordgroup/assets/images/deal.jpg?sa=X&ved=2ahUKEwjskv2RiLCKAxXrJNAFHeTRK1sQ_B16BAgDEAI